Clinical Trials Logo

Filter by:
NCT ID: NCT04097730 Active, not recruiting - Keratitis Bacterial Clinical Trials

Steroids and Cross-linking for Ulcer Treatment

SCUT II
Start date: September 24, 2020
Phase: Phase 3
Study type: Interventional

Steroids and Cross-linking for Ulcer Treatment (SCUT II) is an international, randomized, double-masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus collagen cross-linking (CXL), as well as to further evaluate findings from subgroup analyses of SCUT. Patients presenting to the Aravind Eye Care System (India), Kaiser Permanente Northern California (USA), or the University of California, San Francisco (USA) with smear-positive and/or culture-positive typical (i.e. non-Nocardia or Mycobacteria) bacterial corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of three treatment groups: Group 1: Standard therapy, topical 0.5% moxifloxacin plus topical placebo plus sham CXL Group 2: Early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05% plus sham CXL Group 3: CXL plus early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05% plus CXL

NCT ID: NCT04097340 Active, not recruiting - Substance Use Clinical Trials

Attention Training on Smartphones

ATS
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate a new method that may influence attention, cravings and substance use called attention training, which will be delivered on a smartphone through an application (app). The study team would like to know what participants think of this new method and to determine if research involving this app is feasible. Eligible participants will use the app for a period of two weeks and attend a total of 4 appointments at our study location.

NCT ID: NCT04097119 Active, not recruiting - Health, Subjective Clinical Trials

HDL Function Dietary Supplement Safety and QOL

Start date: September 18, 2019
Phase: N/A
Study type: Interventional

Nutritional supplements are routinely purchased by consumers with suboptimal HDL to support their health, lifestyle and overall quality of life. Many such products receive minimal evaluation prior to marketing. This study aims to evaluate a specific nutritional supplement for its safety, tolerance and acceptability as well as the potential for positive impact on quality of life.

NCT ID: NCT04097028 Active, not recruiting - Clinical trials for Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Start date: December 20, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trifluridine/tipiracil and oxaliplatin work as the first line of treatment (induction) in treating patients with esophageal or gastroesophageal junction adenocarcinoma that can be removed by surgery (resectable). Drugs used in chemotherapy, such as trifluridine/tipiracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT04096742 Active, not recruiting - Photoaging Clinical Trials

Altreno for Chest Rejuvenation

Start date: August 6, 2019
Phase: Phase 4
Study type: Interventional

This is a single-center, prospective, double-blind, randomized, vehicle-controlled study to evaluate the efficacy, safety and patient satisfaction of tretinoin 0.05% lotion (Altreno) for chest rejuvenation.

NCT ID: NCT04096443 Active, not recruiting - Multiple Sclerosis Clinical Trials

Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis

Start date: October 28, 2019
Phase: Early Phase 1
Study type: Interventional

The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.

NCT ID: NCT04096417 Active, not recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.

NCT ID: NCT04095234 Active, not recruiting - Cancer Pain Clinical Trials

Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)

Start date: September 17, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the long-term effectiveness of acupuncture versus massage in people living with advanced cancer. The study will test how the two approaches compare in helping people with pain and its related symptoms and improving quality of life.

NCT ID: NCT04095221 Active, not recruiting - Rhabdomyosarcoma Clinical Trials

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Start date: September 17, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test whether the study drug prexasertib is a safe and effective treatment for people with DSRCT or RMS when given in combination with the standard drugs irinotecan and temozolomide. The study will test different doses of prexasertib in combination with irinotecan and temozolomide to find the highest dose of prexasertib that causes few or mild side effects in participants.

NCT ID: NCT04095052 Active, not recruiting - Folate Deficiency Clinical Trials

Food and Alcohol Behavior Study: Meaningful Enhancement

FAB:ME
Start date: August 14, 2019
Phase: N/A
Study type: Interventional

This study will determine how folate supplementation affects both serum and red blood cell folate status in females ages 18 -24 years old. Additionally, this study will determine the effect of folate supplementation on mood, cognition, and sleep patterns. This study will fill a crucial gap in understanding how folate status affects a variety of health behaviors in order to better inform public health practice and prevention.